公开(公告)号：US20220362196A1

公开(公告)日：2022-11-17

申请号：US17771172

申请日：2020-11-09

Applicant: THE CHILDREN'S HOSPITAL OF PHILADELPHIA

Inventor： Edward M. BEHRENS ,  Chhanda BISWAS

IPC: A61K31/225 ,  A61P37/00 ,  A61K45/06

Abstract: Compositions and methods for treating macrophage activation syndrome are provided.

公开(公告)号：US11491158B2

公开(公告)日：2022-11-08

申请号：US17140471

申请日：2021-01-04

Applicant: Nerviano Medical Sciences S.R.L.

Inventor： Simona Bindi ,  Davide Carenzi ,  Ilaria Motto ,  Maurizio Pulici

IPC: A61K31/519 ,  C07D487/04 ,  C07D513/04 ,  A61P37/00 ,  A61P25/28 ,  A61P35/00 ,  A61K31/4355 ,  A61K31/4365 ,  C07D491/048 ,  C07D495/04

Abstract: The invention relates to N-(substituted-phenyl)-sulfonamide compounds, which are extremely useful as inhibitors of protein kinases (e.g. PERK kinase) and accordingly can be used for the treatment of cell proliferative disorders, such as cancer, or diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

公开(公告)号：US20220340548A1

公开(公告)日：2022-10-27

申请号：US17614854

申请日：2020-05-25

Applicant: Galapagos NV

Inventor： Luke Jonathan ALVEY ,  Denis BUCHER ,  Nicolas DESROY ,  Hélène Marie JARY ,  Christophe PEIXOTO ,  Taoues TEMAL-LAÏB ,  Amynata TIRERA ,  Florence Marie-Emilie BONNATERRE ,  Béranger DUTHION

IPC: C07D405/10 ,  C07D401/10 ,  C07D235/16 ,  C07D471/04 ,  C07D519/00 ,  A61P1/00 ,  A61P19/02 ,  A61P9/00 ,  A61P11/00 ,  A61P37/00

Abstract: The present invention discloses compounds according to Formula I: wherein R1a, R1b, R1c, R2a, W1, W2, X1, X2, X3, Y, and Z are as defined herein.
The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNFα, interferons, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.

公开(公告)号：US11471531B2

公开(公告)日：2022-10-18

申请号：US17132624

申请日：2020-12-23

Applicant: SNIPR Technologies Limited

Inventor： Jasper Clube ,  Morten Sommer ,  Christian Grøndahl

IPC: A61K39/395 ,  A61K39/00 ,  A61P37/00 ,  A61P35/00 ,  A61K31/7105 ,  A61K35/15 ,  A61K35/17

Abstract: The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.

公开(公告)号：US11447573B2

公开(公告)日：2022-09-20

申请号：US16319224

申请日：2017-07-20

Applicant: NANJING LEGEND BIOTECH CO., LTD.

Inventor： Chuan-Chu Chou ,  Yafeng Zhang ,  Shu Wu ,  Zhenyu Liu ,  Zhongdao Li ,  Fangliang Zhang

IPC: C07K16/46 ,  C07K16/28 ,  A61P35/00 ,  A61P37/00 ,  A61P29/00 ,  C07K16/24 ,  C07K16/30 ,  A61K39/00

Abstract: Disclosed herein are multispecific, such as bispecific, antigen binding proteins comprising a first antigen binding domain comprising a heavy chain variable domain and a light chain variable domain, and a second antigen binding domain comprising a single-domain antibody. Pharmaceutical compositions comprising the multispecific antigen binding proteins, kits and methods of use thereof are further provided.

公开(公告)号：US20220289736A1

公开(公告)日：2022-09-15

申请号：US17313319

申请日：2021-05-06

Applicant: Innate Tumor Immunity, Inc.

Inventor： Gary D. Glick ,  Shomir Ghosh ,  William R. Roush ,  Edward James Olhava ,  Daniel O'Malley

IPC: C07D471/04 ,  A61P35/00 ,  A61P37/00 ,  A61K31/4745 ,  A61K31/5377 ,  A61K45/06

Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity (e.g., a condition, disease or disorder associated with an insufficient immune response) that contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

公开(公告)号：US20220280637A1

公开(公告)日：2022-09-08

申请号：US17672571

申请日：2022-02-15

Applicant: ARAVAX PTY LTD

Inventor： Robyn Elizabeth O'Hehir ,  Sara Rachel Prickett ,  Jennifer May Rolland

IPC: A61K39/35 ,  A61K31/7088 ,  A61P37/08 ,  A61K38/08 ,  A61K38/10 ,  A61P37/00

Abstract: The present invention relates generally to an immunotherapeutic composition. More particularly, the present invention relates to an immunotherapeutic composition which interacts immunologically with T lymphocytes in subjects having peanut allergy or allergy to other tree nuts. This composition is preferably immunointeractive with T cells in subjects having an allergy to the Ara h 1 and/or Ara h 2 allergens. The composition of the present invention is useful in the therapeutic or prophylactic treatment of conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to peanut, Ara h 1 and/or Ara h 2 or derivative or homologue thereof.

公开(公告)号：US20220213204A1

公开(公告)日：2022-07-07

申请号：US17613218

申请日：2020-06-03

Applicant: UNIVERSITÄT REGENSBURG ,  UNIVERSITÄT ZU KÖLN MEDIZINISCHE FAKULTÄT

Inventor： HINRICH ABKEN ,  ANDREAS HOMBACH ,  MANUEL EHLING

IPC: C07K16/28 ,  A61K35/17 ,  A61P37/00 ,  C07K14/725 ,  C07K14/705 ,  C07K14/715 ,  C12N5/0783

Abstract: The present invention relates to proteins which comprise (i) a CD25-specific binding domain, (ii) a linker domain, connecting domain (i) and domain (iii), (iii) a transmembrane domain, and (iv) a signalling domain. The present invention furthermore relates to nucleic acids encoding the proteins, expression constructs for expressing the protein in a host cell and host cells. The present invention further relates to pharmaceutical compositions comprising said protein(s), nucleic acid(s), expression construct(s) or host cell(s). The proteins of the invention are CD25-specific chimeric antigen receptors that are suitable for generating CD25-specific immune cells, which can be used e.g. in the treatment of inflammation.

公开(公告)号：US20220213143A1

公开(公告)日：2022-07-07

申请号：US17703111

申请日：2022-03-24

Applicant: ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY ,  UNIVERSITY OF SOUTH AUSTRALIA ,  THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF ,  MONASH UNIVERSITY

Inventor： Stavros SELEMIDIS ,  Doug A. BROOKS ,  John O'LEARY

IPC: C07K7/06 ,  A61P37/00 ,  A61P31/00 ,  A61P29/00 ,  A61P35/00 ,  C07K14/705

Abstract: The present invention relates generally to the field of immunomodulation. Taught herein is an agent for inhibiting immunostimulation mediated by a Toll-like receptor useful in the treatment of viral and microbial pathogenesis, diseases involving elements of autoimmunity and inflammation as well as cancer. The agent antagonizes disulfide bond formation between C98 and C475 of Toll-like receptor 7 (TLR7) thereby preventing TLR7 activation. Pharmaceutical compositions are also enabled herein.

公开(公告)号：US11377480B2

公开(公告)日：2022-07-05

申请号：US16339710

申请日：2017-10-06

Applicant: Poseida Therapeutics, Inc.

Inventor： Eric M. Ostertag ,  Devon Shedlock

IPC: C07K14/47 ,  C07K14/705 ,  A61P37/00 ,  A61P31/00 ,  A61P3/00 ,  A61P17/02 ,  A61P29/00 ,  A61P35/00 ,  A61K35/17 ,  C12N5/0783 ,  C12N9/50 ,  C12N15/52

Abstract: The disclosure provides inducible caspase polypeptides, compositions comprising inducible caspase polypeptides and sequences encoding the same, cells modified to express the polypeptides and compositions of the disclosure, as well as methods of making and methods of using same for adoptive cell therapy.